Dasatinib, a second-generation Abl inhibitor developed to overcome imatinib resistance in chronic myeloid leukaemia (CML), has been recently found to sensitize in vitro chronic lymphocytic leukaemia (B-CLL) cell lines to fludarabine. Furthermore, in B-CLL, dasatinib synergistically sensitizes primary lymphocytes to chlorambucil and fludarabine, prevents CD40-mediated drug resistance and induces a high proapoptotic response in primary lymphocytes obtained from patients with aggressive disease. Herein, we report the case of a 51-year old woman affected by an untreated B-CLL from 42 years of age, who was diagnosed with CML. The patient undewent treatment with dasatinib obtaining a complete hematological and cytogenetic response of CML and a complete clinical remission of B-CLL.
Dasatinib-induced response in a rare case of chronic lymphocytic leukaemia associated with chronic myeloid leukaemia
TECCHIO, Cristina;TODESCHINI, Giuseppe;PIZZOLO, Giovanni;AMBROSETTI, Achille
2009-01-01
Abstract
Dasatinib, a second-generation Abl inhibitor developed to overcome imatinib resistance in chronic myeloid leukaemia (CML), has been recently found to sensitize in vitro chronic lymphocytic leukaemia (B-CLL) cell lines to fludarabine. Furthermore, in B-CLL, dasatinib synergistically sensitizes primary lymphocytes to chlorambucil and fludarabine, prevents CD40-mediated drug resistance and induces a high proapoptotic response in primary lymphocytes obtained from patients with aggressive disease. Herein, we report the case of a 51-year old woman affected by an untreated B-CLL from 42 years of age, who was diagnosed with CML. The patient undewent treatment with dasatinib obtaining a complete hematological and cytogenetic response of CML and a complete clinical remission of B-CLL.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
